Clinical trials: Extensive Disease Small Cell Lung Cancer
Small Cell Lung Cancer
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small…
- Trial name
- NCT07231445
- Testing
- ZG006, Serplulimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Lung Cancer
ZD6474 in Treating Patients With Small Cell Lung Cancer
RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor.
- Trial name
- NCT00066313
- Testing
- vandetanib, adjuvant therapy
- Where
- 21 sites in Canada
- Sponsor
- Genzyme, a Sanofi Company
Small Cell Lung Cancer Extensive Stage
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
Patients with extensive disease SCLC after failure of first-line treatment were enrolled with SHR-1210 and epirubicin for 3 cycles to evaluate initial efficacy
- Trial name
- NCT03755115
- Testing
- Epirubicin plus SHR1210
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Lung Cancer, Metastatic Cancer
Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Heating paclitaxel to several degrees above body temperature and infusing it to the affected area around the…
- Trial name
- NCT00020007
- Testing
- isolated perfusion, paclitaxel, hyperthermia treatment
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
This proposed Phase II trial will investigate the combination of irinotecan and carboplatin followed by sunitinib in the first-line treatment of patients with extensive-stage SCLC.
- Trial name
- NCT00695292
- Testing
- irinotecan, Carboplatin, sunitinib
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- SCRI Development Innovations, LLC
Small Cell Lung Cancer
Trial of BMS-986012 in Combination With Platinum and Etoposide
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
- Trial name
- NCT02815592
- Testing
- BMS-986012, Cisplatin, Etoposide
- Where
- 4 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Extensive-stage Small-cell Lung Cancer
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
- Trial name
- NCT05874401
- Testing
- Trilaciclib, Topotecan
- Where
- Spain
- Volunteers
- 302 people
- Sponsor
- Pharmacosmos A/S
Extensive-stage Small-cell Lung Cancer
Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study
This is a single-arm, real-world study in Chinese patients with extensive stage small cell lung cancer. The purpose of this study was to evaluate Trilaciclib's protection against chemotherapy-induced bone marrow suppression, the…
- Trial name
- NCT05071703
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma
- Trial name
- NCT05353439
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Pulmonary Neoplasms
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
To demonstrate an increase in overall survival for patients with newly diagnosed extended stage small cell lung cancer when treated with SR48692 versus placebo, after an initial response (complete or partial response or stable)…
- Conditions
- Lung Cancer, Pulmonary Neoplasms, Small Cell Lung Cancer
- Trial name
- SESAME (NCT00290953)
- Testing
- SR48692
- Where
- 14 sites in Argentina, Australia and 12 more
- Volunteers
- 432 people
- Sponsor
- Sanofi
Limited Stage Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
In this phase III study, the primary objective is to test with a one-sided significance of 5% whether for the treatment of small cell lung cancer (SCLC) patients, brain MRI surveillance alone is non-inferior in terms of overall…
- Trial name
- PRIMALung (NCT04790253)
- Testing
- Prophylactic cranial irradiation
- Where
- 55 sites in Austria, Belgium and 7 more
- Volunteers
- 600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non Small Cell Lung Cancer, NSCLC
Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Both metastatic squamous non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) are incurable with current therapies, but due to mutations induced by cigarette smoke, typically express a large number…
- Conditions
- Non Small Cell Lung Cancer, NSCLC, Non-small Cell Lung Cancer, Small Cell Lung Extensive Stage
- Trial name
- NCT03166254
- Testing
- Pembrolizumab, NEO-PV-01 vaccine, Biopsy
- Sponsor
- Washington University School of Medicine
Small Cell Lung Cancer, SCLC
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's…
- Conditions
- Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer, Limited Stage Small-Cell Lung Cancer
- Trial name
- MOZART (NCT05903092)
- Testing
- Durvalumab, Monalizumab, Carboplatin or Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Hirva Mamdani
Extensive Stage Small Cell Lung Carcinoma
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
This phase II trial studies how well pembrolizumab and epacadostat work in combination treating patients with extensive stage small cell lung cancer.
- Trial name
- NCT03402880
- Testing
- Pembrolizumab, Epacadostat, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Lung Cancer
Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227565
- Testing
- carboplatin, pemetrexed disodium, radiation
- Where
- 148 sites in United States
- Volunteers
- 50 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Small-cell Lung Cancer
PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study
prophylactic cranial irradiation （PCI）was verified to decrease the brain metastases rates and improve the overall survival（OS）for patients with limited stage small cell lung cancer.We hypothesis that patients with extensive-stage…
- Trial name
- NCT04535739
- Testing
- prophylactic cranial irradiation
- Where
- China
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Small-cell Lung Cancer
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.
- Trial name
- NCT00286169
- Testing
- Amrubicin Hydrochloride
- Where
- 8 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Small Cell Lung Cancer
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
The purpose of the study is to document the activity and safety of single agent amrubicin, amrubicin combined with cisplatin, and etoposide combined with cisplatin as first-line treatment in extensive disease small cell lung…
- Trial name
- NCT00388960
- Testing
- Amrubicin, Cisplatin, Etoposide
- Where
- 25 sites in Belgium, Italy and 3 more
- Volunteers
- 99 people
- Sponsor
- Celgene